Other languages Johnson & Johnson NEO Exchange

Equities

JNJ

CA47817E1034

End-of-day quote NEO Exchange Other stock markets 18:00:00 2024-06-26 EDT			5-day change	1st Jan Change
19.53 ^CAD	-0.76%		-1.46%	-7.66%

06-27	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE
06-24	US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	RE

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	06-24
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	06-24
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06-21
Johnson & Johnson : dossier déposé dans la maladie de Crohn	06-21
Johnson & Johnson : le rachat de Proteologix est bouclé	06-21
Johnson & Johnson Completes Acquisition of Proteologix	06-21
Johnson & Johnson Completes Acquisition of Proteologix	06-21
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	06-20
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	06-20
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	06-20
J&J : lance un écosystème numérique ouvert et sécurisé	06-20
J&J : des résultats prometteurs dans la maladie de Crohn	06-20
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	06-20
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease	06-20
J&J : sollicite la FDA dans le cancer du poumon	06-17
Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer	06-17
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	06-17
J&J : résultat positif dans la maladie de Sjögren	06-17
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	06-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm